Vestmark Advisory Solutions Inc. lifted its position in Certara, Inc. (NASDAQ:CERT – Free Report) by 9.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,791 shares of the company’s stock after buying an additional 1,557 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Certara were worth $429,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Certara by 6.2% in the 3rd quarter. Vanguard Group Inc. now owns 10,652,509 shares of the company’s stock valued at $141,466,000 after acquiring an additional 626,267 shares in the last quarter. William Blair Investment Management LLC lifted its stake in Certara by 32.1% in the 4th quarter. William Blair Investment Management LLC now owns 6,732,603 shares of the company’s stock valued at $108,193,000 after purchasing an additional 1,634,607 shares during the last quarter. BlackRock Inc. increased its position in Certara by 1.1% during the first quarter. BlackRock Inc. now owns 6,540,553 shares of the company’s stock worth $140,491,000 after buying an additional 74,266 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its stake in Certara by 27.6% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 6,129,926 shares of the company’s stock valued at $98,508,000 after buying an additional 1,326,060 shares during the period. Finally, Clearbridge Investments LLC lifted its position in shares of Certara by 1.0% in the fourth quarter. Clearbridge Investments LLC now owns 3,251,400 shares of the company’s stock valued at $52,250,000 after buying an additional 32,069 shares during the last quarter. 67.34% of the stock is currently owned by institutional investors.
Certara Price Performance
Shares of NASDAQ:CERT opened at $16.23 on Friday. Certara, Inc. has a fifty-two week low of $10.60 and a fifty-two week high of $24.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.43 and a current ratio of 3.43. The company’s 50-day moving average is $18.13 and its 200 day moving average is $20.31. The company has a market capitalization of $2.59 billion, a P/E ratio of 135.26, a price-to-earnings-growth ratio of 0.88 and a beta of 1.42.
Insider Buying and Selling
In related news, insider Patrick F. Smith sold 19,104 shares of the stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $21.55, for a total transaction of $411,691.20. Following the completion of the sale, the insider now directly owns 59,975 shares in the company, valued at approximately $1,292,461.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.60% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
CERT has been the subject of several research reports. Credit Suisse Group cut their price target on Certara from $27.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, August 10th. TheStreet downgraded shares of Certara from a “c-” rating to a “d+” rating in a report on Friday, June 16th. William Blair cut shares of Certara from an “outperform” rating to a “market perform” rating in a report on Thursday, August 10th. Barclays reduced their price objective on Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, August 11th. Finally, Bank of America lowered their target price on Certara from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Certara has an average rating of “Moderate Buy” and a consensus price target of $21.71.
Check Out Our Latest Research Report on CERT
Certara Profile
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.
Featured Stories
- Five stocks we like better than Certara
- What Are Dividend Achievers? An Introduction
- 7 Best Bear Market ETFs to Battle a Market Decline
- Comparing and Trading High PE Ratio Stocks
- How to Invest in Wheat: Is it a Hedge Against Inflation?
- Quiet Period Expirations Explained
- Walmart Wins the Retail Wars: Target is Losing Ground
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
